Q2 2025 Puma Biotechnology Inc Earnings Call Transcript
Key Points
- Puma Biotechnology Inc (PBYI) reported total revenue of $52.3 million for Q2 2025, with product revenue net from NERLYNX sales increasing to $49.2 million, up from $43.1 million in Q1 2025.
- The company saw a 12% increase in NERLYNX ex-factory bottle sales quarter over quarter, indicating strong demand.
- Puma's ongoing Phase II trials for alisertib in breast and lung cancer are enrolling ahead of expectations, with interim data expected later in 2025.
- The marketing team has reached 99.7% of oncologists through non-personal promotion, expanding awareness and engagement for NERLYNX.
- Puma reported a GAAP net income of $5.9 million for Q2 2025, demonstrating financial discipline and profitability.
- New prescriptions for NERLYNX were down approximately 3% compared to Q1 2025, indicating a potential challenge in attracting new patients.
- Enrollments decreased by about 9% quarter over quarter and declined about 11% year over year, which could impact future growth.
- The company anticipates lower royalty revenues for 2025 due to fewer shipments expected to China, affecting overall revenue.
- Research and development expenses increased to $15.5 million in Q2 2025, driven by faster enrollments in clinical trials, which could pressure margins.
- Puma's gross to net adjustment for the full year 2025 is expected to be higher than prior guidance due to increased government chargeback expenses.
Good afternoon. My name is Latanya, and I will be your conference call operator today. (Operator Instructions) As a reminder, this call is being recorded.
I would now like to turn the conference over to your host today, Mariann Ohanesian, Senior Director of IR for Puma Biotechnology. You may begin your conference.
Thank you, Latanya. Good afternoon and welcome to Puma's conference call to discuss our earnings results for the second quarter of 2025. Joining me on the call today are Alan Auerbach, Chief Executive Officer, President and Chairman of the Board of Puma Biotechnology; Maximo Nougues, Chief Financial Officer; Heather Blaber, Senior Vice President of Marketing; and Roger Storms, Senior Vice President of Sales.
After the close today, Puma issued a news release detailing earnings results for second-quarter 2025. That news release, the slides that Roger will refer to, and a webcast of this call are accessible via the homepage and investor sections of our website at
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
